Gaelic Laboratories and Athlone Laboratories have announced they will launch a dual-source supply strategy for Beta-Lactam antibiotics at CPHI Milan, following the completion of the first phase of their post-acquisition integration.
The Irish pharma manufacturers said they have aligned manufacturing processes across their two sites to allow customers to source the same Beta-Lactam products from either facility.
The strategy is designed to reduce reliance on a single manufacturing site while providing greater supply continuity for customers.
The companies will showcase the strategy at CPHI Milan, which takes place from 6-8 October 2026, on stand 12A59 in Hall 12.
Integration lays groundwork for dual-source manufacturing
Gaelic Laboratories acquired Athlone Laboratories in December 2025 in a horizontal acquisition that brought together two GMP-approved manufacturers of oral-dose Beta-Lactam products.
At the time, Gaelic said the deal would strengthen its manufacturing capabilities and enable supply-chain efficiencies.
Since the acquisition, the companies have worked to consolidate supply chains and administrative systems, align IT and compliance processes and establish a joint operating model.
Phase I of the integration was completed earlier this year and included operational changes, an internal communications programme and the launch of a joint website.
The companies said the next stage has focused on aligning their manufacturing operations and technology-transfer processes so that products can be manufactured consistently across both sites.
“Both companies benefit from a strategic investment and expansion programme, which continuously improves our technology base,” said Brian Morrissey, General Manager.
"For example, we have been upgrading both sites to ensure they are fully compliant with the latest AMR Industry Alliance Manufacturing Standard."
We have also been strengthening our technology transfer protocols so customers can be fully confident that the Beta-Lactams we manufacture can be produced reliably and consistently, to exactly the same standards and processes, across both manufacturing sites.
Two-site strategy strengthens supply resilience
The combined operation has an annual capacity of 1.2 billion oral dosage forms and serves customers across Ireland, the UK, EU, MENA, Canada and Australia.
The companies said the two-site model will allow customers to access their combined manufacturing capabilities and skilled workforce while reducing the supply risks associated with single-site dependency.
“We are launching the dual source strategy at CPHI Milan in October,” added Morrissey. “Our exhibition stand will showcase the strengths and capabilities of both companies."
We very much look forward to talking to many existing customers and interested new prospects about our vision for shaping the future of Beta-Lactams production in Ireland.
